第二代与第三代化疗方案联合同步胸部放疗治疗不可切除III期非小细胞肺癌的10年随访:WJTOG0105 III期随机临床试验
WJTOG0105研究纳入440例不可切除III期非小细胞肺癌患者,随机接受丝裂霉素/长春地辛/顺铂(A组)、伊立替康/卡铂(B组)或紫杉醇/卡铂(C组)联合胸部放疗60 Gy。中位随访11.9年,三组中位总生存分别为20.5、19.8和22.0个月,10年生存率分别为13.6%、7.5%和15.2%,无显著差异。C组疗效与毒性谱与A组相似,可作为历史对照。
要点
- 三组10年总生存率无显著差异,C组15.2%与A组13.6%相近。
- B组10年生存率7.5%数值较低,但差异未达统计学意义。
- 3/4级晚期毒性以肺为主,A组3.4%、B组3.4%、C组4.1%。
核心结论
- C组(紫杉醇/卡铂)在治疗开始10年后达到与A组(丝裂霉素/长春地辛/顺铂)相似的疗效和毒性谱。
- 三组间总生存无显著差异,结果可作为未来同步放化疗长期比较的历史对照。
研究设计与样本
- 多中心III期随机临床试验(WJTOG0105),2001年9月至2005年9月在日本开展。
- 共纳入440例组织学或细胞学确诊的不可切除III期非小细胞肺癌患者。
- 随机分为A组146例、B组147例、C组147例,中位随访11.9年(范围7.6-13.3年)。
主要发现
- A、B、C组10年生存率分别为13.6%、7.5%、15.2%,组间无显著差异。
- A、B、C组10年无进展生存率分别为8.5%、6.5%、11.1%。
- 3/4级晚期毒性:A组3.4%(心脏0.7%、肺2.7%),B组仅肺3.4%,C组仅肺4.1%。
- 自初次报告以来未观察到其他3/4级晚期毒性事件。
临床怎么用
- 对于不可切除III期NSCLC,紫杉醇/卡铂联合同步胸部放疗60 Gy可作为疗效与毒性平衡的参考方案。
- 长期随访中3/4级晚期毒性以肺为主,需关注放疗后肺毒性监测。
- 该研究结果可作为未来同步放化疗临床试验长期结局比较的历史对照。
局限性
- 研究自2001-2005年入组,方案与当前临床实践可能存在差异。
- 原文未报告组间比较的P值,无法判断差异的统计学意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Insufficient data are available regarding the long-term outcomes and cumulative incidences of toxic effects that are associated with chemoradiotherapy (CRT) for patients with stage III non-small-cell lung cancer. OBJECTIVE: To evaluate survival and late toxic effects 10 years after patients were treated with curative CRT. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, phase 3 West Japan Thoracic Oncology Group (WJTOG) 0105 randomized clinical trial was conducted between September 2001 and September 2005 in Japan. Patients with histologically or cytologically confirmed non-small-cell lung cancer with unresectable stage III disease were assessed for eligibility. Additional data were analyzed from January 2018 to December 2019. INTERVENTIONS: A total of 440 eligible patients were randomly assigned to groups as follows: A (control), 4 cycles of mitomycin/vindesine/cisplatin plus thoracic radiotherapy (TRT) of 60 Gy; B, weekly irinotecan/carboplatin for 6 weeks plus TRT of 60 Gy followed by 2 courses of irinotecan/carboplatin consolidation; or C, weekly paclitaxel/carboplatin for 6 weeks plus TRT of 60 Gy followed by 2 courses of paclitaxel/carboplatin consolidation. MAIN OUTCOMES AND MEASURES: The primary outcome was 10-year survival probability after CRT. The secondary outcome was late toxic effects that occurred more than 90 days after initiating CRT. RESULTS: From September 2001 to September 2005, 440 patients (group A, n = 146 [33.2%; median (range) age, 63 (31-74) years; 18 women (12.3%)]; group B, n = 147 [33.4%; median (range) age, 63 (30-75) years; 22 women (15.0%)]; group C, n = 147 [33.4%; median (range) age, 63 (38-74) years; 19 women (12.9%)]) were enrolled. The median (range) follow-up was 11.9 (7.6-13.3) years. In groups A, B, and C, median (range) overall survival times were 20.5 (17.5-26.0), 19.8 (16.7-23.5), and 22.0 (18.7-26.2) months, respectively, and 10-year survival probabilities were 13.6%, 7.5%, and 15.2%, respectively. There were no significant differences in overall survival among treatment groups. The 10-year progression-free survival probabilities were 8.5%, 6.5%, and 11.1% in groups A, B, and C, respectively. Grade 3 or 4 late toxic effect rates were 3.4% (heart, 0.7%; lung, 2.7%) in group A, and those only affecting the lung represented 3.4% and 4.1% in groups B and C, respectively. No other cases of late toxic effects (grades 3/4) were observed since the initial report. CONCLUSION AND RELEVANCE: In this 10-year follow-up of a phase 3 randomized clinical trial, group C achieved similar efficacy and toxic effect profiles as group A 10 years after initiating treatment. These results serve as a historical control for the long-term comparisons of outcomes of future clinical trials of CRT. TRIAL REGISTRATION: UMIN Clinical Trial Registry: UMIN000030811.
引用
- Zenke Y, Tsuboi M, Chiba Y, et al. Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non-Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 33734289. doi:10.1001/jamaoncol.2021.0113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。